Cardinal Health Inc. stock (US14149Y1082): shares hover around USD 195 as Fortune 500 ranking underscores scale

Cardinal Health Inc. shares on the NYSE traded just under USD 195 this week, while the healthcare distributor again ranked 15th on the 2026 Fortune 500 list with USD 223 billion in fiscal 2025 revenue, highlighting its scale in the United States market.

Cardinal Health Inc. shares on the New York Stock Exchange have been trading broadly sideways this week, with the stock closing around USD 194.88 on 06/02/2026, only fractionally lower than the prior day, according to price data for NYSE:CAH as of that date.StockInvest as of 06/02/2026 The United States-based healthcare services group remains one of the largest distributors in its home market, and its current share price levels come as the company has once again secured a prominent position in the newly released 2026 Fortune 500 ranking.

On 06/03/2026, local business media reported that Dublin, Ohio-headquartered Cardinal Health retained the number 15 spot in the latest Fortune 500 list, supported by fiscal 2025 revenue of USD 223 billion and confirming its role as Ohio's largest company by sales.Columbus Business First as of 06/03/2026 The stock trades in US dollars on the NYSE under the ticker CAH, linking its performance closely to the broader US healthcare distribution and services sector.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Cardinal Health
• Sector/industry: Healthcare distribution and services
• Headquarters/country: Dublin, United States
• Core markets: United States, with selected international operations
• Key revenue drivers: Pharmaceutical distribution, medical products, and specialty solutions
• Home exchange/listing venue: New York Stock Exchange (CAH)
• Trading currency: USD

Cardinal Health Inc.: core business model

Cardinal Health Inc. operates as a large-scale healthcare distributor and solutions provider, generating most of its revenue by supplying pharmaceuticals and medical products as well as related services to hospitals, pharmacies, and other care providers.

Cardinal Health Inc. in peer comparison

In the United States healthcare distribution space, Cardinal Health competes with players such as McKesson and AmerisourceBergen, which also focus on large-volume pharmaceutical and medical supply chains for providers and pharmacies.StockAnalysis as of 06/02/2026 While each company has its own mix of contracts and specialty services, all three share exposure to US prescription drug volumes, reimbursement dynamics, and operational efficiency in logistics-intensive businesses.

Recent data for Cardinal Health show a market capitalization of around USD 45.64 billion as of 06/02/2026, reflecting an increase of more than 25% year-on-year as the company benefitted from steady demand in its core pharmaceutical and medical product distribution activities.StockAnalysis as of 06/02/2026 That scale places Cardinal Health broadly in line with the multi-tens-of-billions valuation range of its closest distribution peers, underscoring how investor sentiment across the group is influenced by factors such as drug pricing trends, generic utilization, and cost control in supply chains.

Conclusion

The latest trading data place Cardinal Health Inc. shares around USD 195 on the NYSE at the beginning of June 2026, with the stock moving only marginally day-on-day as the broader US healthcare distribution sector digests ongoing industry trends. The confirmation of Cardinal Health's number 15 ranking in the 2026 Fortune 500 list, backed by USD 223 billion in fiscal 2025 revenue, highlights the company's scale relative to its peers and underscores why it remains a central name in US healthcare logistics.

In comparison with other major distributors such as McKesson and AmerisourceBergen, investors in Cardinal Health continue to focus on factors like volume growth, margins in pharmaceutical and medical product distribution, and operational efficiency when assessing the stock's medium-term prospects.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.